根据需要进行的布罗卢齐祖马布和阿弗利塞普特之间的1年结果对多性冠状血管病变的比较
Yoshiko Fukuda1, Yoichi Sakurada2, Mio Matsubara1
1Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3821, Japan.
Japanese journal of ophthalmology
|June 8, 2023
概括
布罗卢齐祖马布和阿弗利柏塞特在一年的时间里显示出可比的视觉和解剖结果,用于多性胆道血管病变 (PCV). 布罗卢齐祖马布需要更少的额外注射,证明了其在根据需要的治疗方案中的有效性.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 血管异常 血管异常
背景情况:
- 多性冠状血管病变 (PCV) 是一种与年龄相关的黄斑变性的一种亚型.
- 视内注射是PCV的主要治疗方法,旨在改善视力敏度和减少视网膜厚度.
- 比较像布罗卢齐祖马布这样的新药与像阿弗利伯塞普特这样的既定治疗方法,对于优化患者护理至关重要.
研究的目的:
- 为了比较brolucizumab与aflibercept在多性胆道血管病变 (PCV) 的一年视觉和解剖结果.
- 评估PCV患者对两种药物的必要治疗方案的有效性.
主要方法:
- 这是一项追溯性比较研究,涉及56个眼睛的56名以前未接受过治疗的PCV患者.
- 患者最初每三个月接受阿弗利伯塞普特 (33只眼睛) 或布罗卢齐祖马布 (23只眼睛) 的静脉内注射,然后根据需要给予.
- 在基线,3个月和12个月进行了每月的随访和成像 (光素和氨酸绿色血管造影).
主要成果:
- 在12个月后,brolucizumab和aflibercept两组都显示出最佳校正视力敏度的显著改善,以及中枢视网膜厚度和亚叶胆道厚度的减少.
- 与aflibercept组 (2.9) 相比,brolucizumab组需要显著减少额外注射 (1.3) 的情况.
- 在ICGA上,多头状病变的完全消失在3个月和12个月的布罗卢齐祖马布组中都更高.
结论:
- 根据需要的布罗卢齐祖马布在一年内在未经治疗的PCV眼睛中表现出与aflibercept相似的视觉和解剖结果.
- 与aflibercept相比,brolucizumab的按需治疗方案导致了较少的补充注射.
- 布罗卢齐祖马布为PCV提供了一种可行的替代治疗选择,在潜在的较少剂量的情况下提供类似的疗效.
关键词:
根据需要的治疗方案.布罗卢西祖马布 (brolucizumab) 是一种药物.额外注射的数量 额外注射的数量聚类型的冠状血管病变 (Polypoidal choroidal vasculopathy) 是一种多重的血管病变.更多相关视频
06:19Comparison of Three Clinical Stereoscopic Methods for Measuring Binocular Visual Function During Amblyopic Treatment in Unilateral Amblyopia
Published on: September 27, 2024
265
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.2K
相关概念视频
01:27Open Angle Glaucoma: Treatment
497
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
497
01:28Angle Closure Glaucoma: Treatment
582
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
582